15 assets in Infiltrating Bladder Urothelial Carcinoma

Therapeutic assets addressing Infiltrating Bladder Urothelial Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) Infiltrating Bladder Urothelial Carcinoma	Fred Hutchinson Cancer Center	P2/3	B (62)
Nivolumab Infiltrating Bladder Urothelial Carcinoma	National Cancer Institute (NCI)	P2/3	B (62)
Pembrolizumab Infiltrating Bladder Urothelial Carcinoma	Fred Hutchinson Cancer Center	P2/3	B (62)
Cis-Diamminedichloroplatinum Ii Infiltrating Bladder Urothelial Carcinoma	Vasgene Therapeutics, Inc	P2/3	B (57)
Relatlimab Infiltrating Bladder Urothelial Carcinoma	National Cancer Institute (NCI)	P2/3	B (57)
Recombinant Ephb4-Hsa Fusion Protein Infiltrating Bladder Urothelial Carcinoma	Vasgene Therapeutics, Inc	P2/3	CCC (55)
Atezolizumab Infiltrating Bladder Urothelial Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Cabozantinib Infiltrating Bladder Urothelial Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ipilimumab Infiltrating Bladder Urothelial Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 Infiltrating Bladder Urothelial Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
[177lu]lu-dpi-4452 Infiltrating Bladder Urothelial Carcinoma	ITM Oncologics GmbH	P1/2	CCC (48)
[68ga]ga-dpi-4452 Infiltrating Bladder Urothelial Carcinoma	ITM Oncologics GmbH	P1/2	CCC (48)
Quemliclustat Infiltrating Bladder Urothelial Carcinoma	Fred Hutchinson Cancer Center	P1/2	CC (47)
Optimized Neoantigen Synthetic Long Peptide Vaccine Infiltrating Bladder Urothelial Carcinoma	Washington University School of Medicine	P1	CC (43)